By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Takeda Pharmaceutical Company Ltd. et. al. v. Teva Pharmaceuticals USA Inc. et. al.
1:07-cv-00331; filed May 25, 2007 in the District Court of Delaware
Infringement of U.S. Patent Nos. 4,628,098 ("2-[2-Pyridylmethylthio-(Sulfinyl)]Benzimidazoles," issued December 9, 1986), 5,045,321 ("Stabilized Pharmaceutical Composition and Its Production," issued September 3, 1991), 5,464,632 ("Rapidly Disintegratable Multiparticular Tablet," issued December 7, 1995), and 6,328,994 ("Orally Disintegrable Tablets," issued December 11, 2001) following a paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of plaintiff's Prevacid® SoluTab
Teva Pharmaceutical Industries Ltd. et. al. v. Torrent Pharmaceuticals Ltd. et. al.
1:07-cv-00332; filed May 25, 2007 in the District Court of Delaware
Declaratory judgment of infringement of U.S. Patent Nos. 6,600,073 ("Methods for Preparation of Sertraline Hydrochloride Polymorphs," issued July 29, 2003), 6,500,987 ("Sertraline Hydrochloride Polymorphs," issued December 31, 2002), 6,495,721 ("Sertraline Hydrochloride Form II and Methods for the Preparation Thereof," issued December 17, 2002), and 6,897,340 ("Processes for Preparation of Polymorphic Form II of Sertraline Hydrochloride," issued May 24, 2005), all directed to methods of manufacturing crystalline forms of sertraline hydrochloride (the API in Pfizer's Zoloft®, used to treat depression) based on defendant's anticipated manufacture and sale of generic Zoloft®. View the complaint here.
Cornerstone BioPharma, Inc. et. al. v. Provident Pharmaceuticals, LLC et. al.
5:07-cv-00192; filed May 25, 2007 in the Eastern District of North Carolina
Infringement of U.S. Patent No. 6,270,796 ("Antihistamine/Decongestant Regimens for Treating Rhinitis," issued August 7, 2001) based on defendants' manufacture (and sale to Breckenridge for distribution and sale) of Breckenridge's Allergy DN, allegedly a "generic" version of Cornerstone's AlleRx® formulations (used to treat allergies and symptoms of the common cold). View the complaint here.
Aventis Pharmaceuticals Inc. et. al. v. Sandoz Inc.
2:07-cv-02454; filed May 24, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 6,399,632 ("Method of Providing an Antihistaminic Effect in a Hepatically Impaired Patient," issued June 4, 2002), 6,187,791 (same title, issued February 13, 2001), and 6,037,353 (same title, issued March 14, 2000) following a paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Aventis' Allegra® and Allegra-D® (fexofenadine hydrochloride, and fexofenadine hydrochloride/ pseudoephedrine, used to treat allergies). View the complaint here.
Comments